Therapeutic proteins and nanotechnology: Immune response and stealth bioengineered constructs

Current Drug Metabolism

Volumn 14, Issue 5, 2013, Pages 531-539

  Lopez Marin, Luz M ^a   Tamariz, Elisa ^b   Acosta Torres, Laura S ^c   Castaño, Victor M ^a  

^a CENTRO DE FÍSICA APLICADA Y TECNOLOGÍA AVANZADA   (Mexico)

^b UNIVERSIDAD VERACRUZANA   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

"smart" PEG conjugates; Drug clearance; Drug metabolism; Engineered nanoparticles; Immune response to nanoparticles; Innate immunity; PEGylation

Indexed keywords

ALBUMIN; BETA INTEGRIN; CHEMOKINE; COMPLEMENT RECEPTOR; CRYOPYRIN; CYTOKINE; ENDOTOXIN; FC RECEPTOR; INFLAMMASOME; LIPOSOME; MACROGOL; MANNOSE RECEPTOR; MONOCLONAL ANTIBODY; NANOPARTICLE; NONIONIC SURFACTANT; OPSONIN; PLASMA PROTEIN; POLYSTYRENE; RECOMBINANT PROTEIN; VACCINE;

ARTICLE; CHEMICAL MODIFICATION; CHEMISTRY; CIRCULATION TIME; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG STABILITY; DRUG SURFACE CHEMISTRY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; INTRACELLULAR MEMBRANE; LEUKOCYTE; LIPOSOMAL DELIVERY; MECHANICAL STRESS; MOLECULAR RECOGNITION; MONOCYTE; NANOENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; POLYMERIZATION; PROTEIN ENGINEERING; PROTEIN PROTEIN INTERACTION; RETICULOENDOTHELIAL SYSTEM; SIGNAL TRANSDUCTION; THROMBOCYTE;

ANIMALS; BIOENGINEERING; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, INNATE; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; POLYETHYLENE GLYCOLS;

EID: 84881639252     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/13892002113149990006     Document Type: Article

References (98)

1. Ryu, D. D.; Nam, D. H. Recent progress in biomolecular engineering. Biotechnol. Prog., 2000, 16, 2-16. (Pubitemid 30097644)
2. Lowe, D.; Jermutus, L. Combinatorial protein biochemistry for therapeutics and proteomics. Curr. Pharm. Biotechnol., 2004, 5, 17-27. (Pubitemid 38404703)
3. Jain, K. K. The handbook of Nanomedicine, Humana Press, 2008, New Jersey, U. S. A., 403 pp.
4. Allen, T. M.; Cullis, P. R. Drug delivery systems: entering the mainstream. Science, 2004, 303, 1818-1822. (Pubitemid 38374867)
5. Anderson, G. F.; Chu, E. Expanding priorities - Confronting chronic diseases in countries with low income. N. Engl. J. Med., 2007, 356, 209-211. (Pubitemid 46143222)
6. Medzhitov, R.; Janeway, C. A. Jr. Innate Immunity: the virtues of a nonclonal system of recognition. Cell, 1997, 91, 295-298. (Pubitemid 27467959)
7. Wang, Y.-Y.; Lai, S. K.; Suk, J. S.; Pace, A.; Cone, R.; Hanes, J. Adressing the PEG mucoadhesivity paradox to engineer nanoparti-cles that "slip" through the human mucus barrier. Angew. Chem. Int. Ed. 2008, 47, 9726-9729.
8. Merrell, D. S.; Falkow, S. Frontal and stealth attack strategies in microbial pathogenesis. Nature, 2004, 430, 250-256. (Pubitemid 38902438)
9. Schnell, M. J.; McGettigan, J. P.; Wirblich, C.; Papaneri, A. The cell biology of rabies virus: using stealth to reach the brain. Nature Rev. Microbiol., 2010, 8, 51-61.
10. Torrelles, J. B.; Schlesinger, L. S., Diversity in Mycobacterium tuberculosis mannosylated cell wall determinants impacts adaptation to the host. Tuberculosis, 2010, 90, 84-93.
11. Bocca, C.; Caputo, O.; Cavalli, R.; Gabriel, L.; Miglietta, A.; Gasco, M. R. Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int. J. Pharm., 1998, 175, 185-193. (Pubitemid 28517974)
12. Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C., Factors affecting the clearance and biodistribution of polymeric nanoparti-cles. Mol. Pharm., 2008, 5, 505-15.
13. Breunig, M.; Bauer, S.; Goepferich, A., Polymers and nanoparti-cles: intelligent tools for intracellular targeting? Eur. J. Pharm. Biopharm., 2008, 68, 112-28. (Pubitemid 350181412)
14. Christian, D. A.; Cai, S.; Bowen, D. M.; Kim, Y.; Pajerowski, J. D.; Discher, D. E., Polymersome carriers: from self-assembly to siRNA and protein therapeutics. Eur. J. Pharm. Biopharm., 2009, 71, 463-474.
15. Cho, K.; Wang, X.; Nie, S.; Chen, Z. G.; Shin, D. M., Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res., 2008, 14, 1310-6. (Pubitemid 351413909)
16. Sperisen, P.; Schmid, C. D.; Bucher, P.; Zilian, O. Stealth proteins: in silico identification of a novel family rendering bacterial pathogens invisible to host immune defense. PLoS Comput. Biol., 2005, 1, 492-499.
17. Abuchowski, A.; McCoy, J. R.; Palczuk, N. C.; van Es, T.; Davis, F. F. Effect of covalent attachment of polyethylene glycol on im-munogenicity and circulating life of bovine liver catalase. J. Biol. Chem., 1977, 252, 3582-3586. (Pubitemid 8116088)
18. Han, M. H.; Chen, J.; Wang, J.; Chen, S. L.; Wang, X. T. Blood compatibility of polyamidoamine dendrimers and erythrocyte protection. J. Biomed. Nanotechnol., 2010, 6, 82-92.
19. Semrau, S.; Monster, M. W. L.; van der Knaap, M.; Florea, B. I.; Schmidt, T.; Overhand, M. Membrane lysis by gramicidin S visualized in red blood cells and giant vesicles. Biochim. Biophys. Acta, 2010, 1798, 2033-2039.
20. Owens, D. E., 3rd; Peppas, N. A., Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 2006, 307, 93-102. (Pubitemid 41773257)
21. Illum, L.; Davis, S. S.; Muller, R. H.; Mak, E.; West, P. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a blockcopolymer-Poloxamine 908. Life Sci., 1987, 40, 367-374.
22. Gref, R.; Domb, A.; Quellec, P.; Blunk, T.; Muller, R. H.; Verbavatz, J. M.; Langer, R. The controlled intravenous delivery o drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug De-liv. Rev., 1995, 16, 215-233.
23. Panagi, Z.; Beletsi, A.; Evangelatos, G.; Livaniou, E.; Ithakissios, D. S.; Avgoustakis, K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int. J. Pharm., 2001, 221, 143-152. (Pubitemid 32524042)
24. th Edition, Lippincott Williams & Wilkins, Philadelphia, PA, U. S. A., 2008.
25. Aderem, A.; Underhill, D. M., Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol., 1999, 17, 593-623. (Pubitemid 29241135)
26. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Benoit, J.-P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials, 2006, 27, 4356-4373. (Pubitemid 43674179)
27. Sant, S., Poulin, S., Hildgen, P. Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interaction of pegylated nanoparticles. J. Biomed. Mat. Res. Part A, 2008, 87A, 885-895.
28. Frank, M. M.; Fries, L. F., The role of complement in inflammation and phagocytosis. Immunol. Today, 1991, 12, 322-6.
29. Moghimi, S. M.; Hunter, A. C., Capture of stealth nanoparticles by the body's defences. Crit. Rev. Ther. Drug Carrier Syst., 2001b, 18, 527-50. (Pubitemid 34024395)
30. Brevig, T.; Holst, B; Ademovic, Z.; Rozlosnik, N.; Rohrmann, H.; Larsen, N. B.; Hansen, O. C.; Kingshott, P. The recognition of adsorbed and denatured proteins of different topographies by beta2 integrins and effects on leukocyte adhesion and activation. Biomaterials, 2005, 26, 3039-3053. (Pubitemid 39647239)
31. Kanno, S.; Furuyama, A.; Hirano, S. A murine scavenger receptor MARCO recognizes polystyrene nanoparticles. Toxicol. Sci., 2007, 97, 398-406. (Pubitemid 47073855)
32. Plourde, N. M.; Kortagere, S.; Welsh, W.; Moghe, P. V. Structure-activity relations of nanolipoblockers with the atherogenic domain of human macrophage scavenger receptor A. Biomacromolecules, 2009, 10, 1381-1391.
33. Yang, R. B.; Mark, M. R.; Gray, A.; Huang, A.; Xie, M. H.; Zhang, M.; Goddard, A.; Wood, W. I.; Gurney, A. L.; Godowski, P. J. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signaling. Nature, 1998, 395, 284-288. (Pubitemid 28447554)
34. Iwasaki, A.; Medzhitov, R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327, 291-295.
35. Martinon, F.; Petrilli, V.; Mayor, A.; Tardiv el, A.; Tschopp, J. Gout-associated uric acid cristals actívate the NALP4 inflamma-some. Nature, 2006, 440, 237-241. (Pubitemid 43372104)
36. Dostert, C.; Petrilli, V.; van Bruggen, R.; Steele, C., Mossman, B. T.; Tschopp, J. Innate immune activation through Nalp3 inflamma-some sensing of asbestos and silica, Science, 2006, 320, 674-677.
37. Hornung, V.; Bauernfeind, F.; Halle, A.; Samstad, E. O.; Kono, H.; Rock, K. L.; Fitzgerald, K. A.; Latz, E. Silica crystals and aluminum salts activate the NALP3 inflammasomes through phagosomal destabilization. Nat. Immunol., 2008, 9, 847-856.
38. Latz, E. The inflammasomes: mechanisms of activation and function. Curr. Opin. Immunol., 2010, 22, 28-33.
39. Bartneck, M.; Keul, H. A.; Zwadlo-Klarwasser, G.; Groll, J. Phagocytosis independent extracellular nanoparticles clearance by human immune cells. Nanolett., 2010, 10, 59-63.
40. Morishige, T.; Yoshioka, Y.; Inakura, H.; Tanabe, A.; Yao, X.; Narimatsu, S.; Monobe, Y.; Imazawa, T.; Tsunoda, S.; Tsutsumi, Y.; Mukai, Y.; Okada, N.; Nakagawa, S. The effect of surface modification of amorphous silica particles on NLRP3 inflamma-some mediated IL-1beta production, ROS production and endosomal rupture. Biomaterials, 2010, 31, 6833-6842.
41. Demento, S. L.; Eisenbarth, S. C.; Foellmer, H. G.; Platt, C.; Caplan, M. J.; Saltzman, W. M.; Mellman, I.; Ledizet, M.; Fikrig, E.; Flavell, R. A.; Fahmy, T. M., Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine, 2009, 27, 3013-3021.
42. Mueller, K. L. Recognizing the first responders, Science, 2010, 327, 283.
43. Schiffelers, R. M.; Storm. G. Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells. Int. J. Pharm., 2008, 364, 258-264.
44. Clapp, C.; Thebault, S.; Jeziorski, M. C.; Martínez de la Escalera, G. Peptide hormone regulation of angiogenesis. Physiol. Rev., 2009, 89, 1177-1215.
45. Thurston, G.; McLean, J. W.; Rizen, M.; Baluk, P.; Haskell, A.; Murphy, T. J.; Hanshan, D. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest., 1998, 101, 1401-1413. (Pubitemid 28166838)
46. Koren, E.; Zuckerman, L. A.; Mire-Sluis, A. R. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr. Pharm., 2002, 349-360. (Pubitemid 35364009)
47. Schellekens, H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. 2002, 24, 1720-1740.
48. Ranade, V. V. Drug delivery systems 5B. Oral drug delivery. J. Clin. Pharmacol., 1991, 31, 98-115.
49. Fu, Y.; Kao, W. J. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin. Drug Deliv., 2010, 7, 429-44.
50. Joralemon, M. J.; McRae, S.; Emrick, T., PEGylated polymers for medicine: from conjugation to self-assembled systems. Chem. Commun, (Camb), 2010, 46, 1377-1393.
51. Lee, K.; Silva, E. A.; Mooney, D. J., Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J. R. Soc. Interface, 2011, 8, 153-70.
52. Murthy, S. K. Nanoparticles in modern medicine: state of the art and future challenges. Int. J. Nanomed. 2007, 2, 129-141. (Pubitemid 47215015)
53. Desai, M. P.; Labhasetwar, V.; Amidon, G. L.; Levy, R. J., Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res., 1996, 13, 1838-45. (Pubitemid 27034116)
54. Sun, X.; Rossin, R.; Turner, J. L.; Becker, M. L.; Joralemon, M. J.; Welch, M. J.; Wooley, K. L., An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PE-Gylation on in vivo biodistribution. Biomacromolecules, 2005, 6, 2541-54. (Pubitemid 41388265)
55. Nagayama, S.; Ogawara, K.; Fukuoka, Y.; Higaki, K.; Kimura, T., Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int. J. Pharm., 2007, 342, 215-21. (Pubitemid 47259322)
56. Desai, M. P.; Labhasetwar, V.; Walter, E.; Levy, R. J.; Amidon, G. L., The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res., 1997, 14, 1568-73. (Pubitemid 28009208)
57. Zauner, W.; Farrow, N. A.; Haines, A. M., In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density. J. Control. Release, 2001, 71, 39-51. (Pubitemid 32195440)
58. Chiannilkulchai, N.; Ammoury, N.; Caillou, B.; Devissaguet, J. P.; Couvreur, P., Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother. Pharmacol., 1990, 26, 122-6. (Pubitemid 20153803)
59. Hu, J.; Liu, Z. S.; Tang, S. L.; He, Y. M., Effect of hydroxyapatite nanoparticles on the growth and p53/c-Myc protein expression of implanted hepatic VX2 tumor in rabbits by intravenous injection. World J. Gastroenterol., 2007, 13, 2798-802. (Pubitemid 47007893)
60. Xi-Xiao, Y.; Jan-Hai, C.; Shi-Ting, L.; Dan, G.; Xv-Xin, Z., Poly-butylcyanoacrylate nanoparticles as a carrier for mitomycin C in rabbits bearing VX2-liver tumor. Regul. Toxicol. Pharmacol., 2006, 46, 211-7. (Pubitemid 44692908)
61. Adler, A. F.; Leong, K. W. Emerging links between surface nanotechnology and endocytosis: Impact on nonviral gene delivery. Nano Today, 2010, 5, 553-69.
62. Dauty, E.; Remy, J. S.; Zuber, G.; Behr, J. P. Intracellular delivery of nanometric DNA particles via the folate receptor. Bioconjug. Chem., 2002, 13, 831-9. (Pubitemid 34801126)
63. Cedervall, T.; Lynch, I.; Lindman, S.; Berggard, T.; Thulin, E.; Nilsson, H.; Dawson, K. A.; Linse, S. Understanding the nanopar-ticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 2050-5. (Pubitemid 46391350)
64. Dell'Orco, D.; Lundqvist, M.; Oslakovic, C.; Cedervall, T.; Linse, S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One, 2010, 5, e10949.
65. Kishore, U.; Reid, K. B. C1q: structure, function, and receptors. Immunopharmacol., 2000, 49, 159-70. (Pubitemid 30445227)
66. Carrstensen, H.; Muller, R. H.; Muller, B. W. Particle size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model drug carriers as parameters related to RES uptake. Clin. Nutr., 1992, 11, 289-97.
67. Norman, M. E.; Williams, P.; Illum, L. Human serum albumin as a probe for surface conditioning (opsonization) of block copolymer-coated microspheres. Biomaterials, 1992, 13, 841-9.
68. Thiele, L.; Rothen-Rutishauser, B.; Jilek, S.; Wunderli-Allenspach, H.; Merkle, H. P.; Walter, E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J. Control. Release, 2001, 76, 59-71. (Pubitemid 32786885)
69. Pichon, C.; Billiet, L; Midoux, P. Chemical vectors for gene delivery: uptake and intracellular trafficking. Curr. Opin. Biotechnol., 2010, 21, 1-6.
70. Ruckenstein, E.; Gourisankar, S. V. Preparation and characterization of thin film surface coatings for biological environments. Biomaterials, 1986, 7, 403-422.
71. Ratner, B. C., Hoffman, A. S., Hanson, S. R., Harker, L. A., Whiffen, J. D. J. Polym Sci. Polym Symp. 1979, 66, 363-372.
72. Meng, F.; Engbers, G. H. M.; Gessner, A.; Muller, R. H.; Feijen, J. Pegylated polystyrene particles as a model system for artificial cells. J. Biomed. Mater. Res., 2004, 70A, 97-106. (Pubitemid 38849816)
73. Harris, J. M.; Chess, R. B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov., 2003, 2, 214-21. (Pubitemid 37361666)
74. Rouzes, C.; Gref, R.; Leonard, M.; de Sousa Delgado, A.; Dellacherie, E. Surface modification of poly(lactic acid) nanospheres using hydrophobically modified dextrans as stabilizers in an o/w emulsion/evaporation technique. J. Biomed. Mater. Res. 2000, 5, 557-565. (Pubitemid 30225382)
75. Woodle, M. C. Controlling liposome blood clearance by surface-grafted polymers. Adv. Drug Deliv. Rev. 1998, 32, 139-152. (Pubitemid 28277180)
76. Dupeyrón, D.; Rieumont, J.; González, M.; Castaño, V. M. Protein delivery by enteric copolymer nanoparticles. J. Dispersion Sci. Technol., 2009, 30, 1188-1194.
77. Wattendorf, U.; Merkle, H. P. PEGylation as a tool for biomedical engineering of surface modified microparticles. J. Pharm. Sci., 2008, 97, 46554-46569.
78. Roberts, M. J.; Bentley, M. D.; Harris, J. M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev., 2002, 54, 459-476. (Pubitemid 34615543)
79. Brocchini, S.; Godwin, A.; Balan, S.; Choi, J.-W.; Zloh, M.; Shaunak, S. Disulfide bridge based PEGylation of proteins. Adv. Drug Deliv. Rev., 2008, 60, 3-12. (Pubitemid 350181163)
80. Hsiao, V. K. S.; Waldeisen, J. R.; Zheng, Y.; Lloyd, P. F.; Bunning, T. J.; Huang, T. J. Aminopropyltriethoxysilane (APTES)-functionalized nanoporous polymeric gratings: fabrication and application in biosensing. J. Mater. Chem., 2007, 17, 4896-4901. (Pubitemid 350176535)
81. Chen Yong Kah, J.; Yi Wong, K.; Gee Neoh, K.; Hang Song, J.; Wei Ping Fu, J.; Mhaisalkar, S.; Olivo, M.; Sheppard, C. J. Critical parameters in the pegylation of gold nanoshells for biomedical applications: An in vitro macrophage study. J. Drug Target., 2009, 17, 181-193.
82. Osada, K.; Christie, R. J.; Kataoka, K. Polyeric micelles from poly(ethylene glicol)-poly(amino acid) block copolymer for drug and gene delivery. J. R. Soc. Interface, 2009, 6, S325-S339.
83. Mukai, Y.; Yoshioka, Y.; Tsutsumi, Y. Phage display and PEGylation of therapeutic proteins. Comb. Chem. High Throughput Screen, 2005, 8, 145-152. (Pubitemid 40388741)
84. Kumagai, I.; Asano, R.; Nakanishi, T.; Hashikami, K.; Tanaka, S.; Badran, A., Sanada, H.; Umetsu, M. Integration of PEGylation and refolding for renaturation of recombinant proteins from insoluble aggregates produced in bacteria - Application to a single-chain Fv fragment. J. Biosci. Bioeng., 2010, 109, 447-452.
85. Jevsevar, S.; Kunstelj, M.; Gaberc Porekar, V. PEGylation of therapeutic proteins. Biotechnol. J., 2010, 5, 113-128.
86. Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U. S. Poly (ethylene glycol) in drug delivery: Pros and Cons as well as potential alternatives. Angew. Chem. Int. Ed., 2010, 49, 6288-308.
87. Bao, S.; Thrall, B. D.; Gies, R. A.; Miller, D. L. In vivo transfection of melanoma cells by lithotripter shock waves. Cancer Release, 1998, 58, 219-21. (Pubitemid 28047057)
88. Ishida, T.; Harada, M.; Wan, X. Y.; Ichihara, M.; Irimura, K.; Kiwada, H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J. Control. Release, 2005, 105, 305-17. (Pubitemid 40941995)
89. Ishida, T.; Wang, X. Y.; Shimizu, T.; Nawata, K.; Kiwada, H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J. Control. Release, 2007, 122, 349-55. (Pubitemid 47407760)
90. Wang, X. Y.; Ishida, T.; Kiwada, H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Release, 2007, 119, 236-44. (Pubitemid 46759557)
91. Hamad, I.; Hunter, A. C.; Szebeni, J.; Moghimi, S. M. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol., 2008, 46, 225-32.
92. Ma, Y.; Yang, Q; Wang, L.; Zhou, X.; Zhao, Y.; Deng, Y. Repeated injection of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats. Eur. J. Pharm. Sci., 2012, 45, 539-45.
93. Judge, A.; McClintock, K.; Phelps, J. R.; MacLachlan, I. Hyper-sensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther., 2006, 13, 328-37. (Pubitemid 43056898)
94. Sherman, M. R.; Williams, L. D.; Sobczyk, M. A.; Michaels, S. J.; Saifer, M. G. P. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconj. Chem., 2012, 23, 485-99.
95. Chambers, E.; Mitragotri, S. Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes. J. Control. Release, 2004, 100, 111-119. (Pubitemid 39451782)
96. Chambers, E.; Mitragotri, S. Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation. Exp. Biol. Med., 2007, 232, 958-966. (Pubitemid 47026803)
97. Romberg, B.; Hennink, W. E.; Storm, G., Sheddable coatings for long-circulating nanoparticles. Pharm. Res., 2008, 25, 55-71.
98. Filpula, D.; Zhao, H., Releasable PEGylation of proteins with customized linkers. Adv. Drug Deliv. Rev., 2008, 60, 29-49. (Pubitemid 350181165)